Salesforce Downgraded to Sell by Guggenheim
Salesforce (CRM) faces a downgrade to Sell from Neutral by Guggenheim, targeting $247. Concerns over Agentforce's monetization potential impact outlook.
Topic
CRM
A collection of 7 issues
Salesforce Set to Capitalize on AI Growth in 2025
Salesforce is positioned as a major player in the AI-driven software boom of 2025, with analysts forecasting substantial growth in the sector.
Salesforce Leverages AI Agents for Enterprise Transformation
Discover how Salesforce is leading the shift towards advanced AI solutions, enhancing enterprise operations with innovative AI agents.
Salesforce Targets Pharmaceutical Sector with New Life Sciences Product
Salesforce expands into the pharmaceutical industry by capturing Veeva's clients and introducing a life sciences product, boosting its market presence.
Salesforce Secures Major Pharma CRM Deals
Salesforce expands into pharmaceutical CRM, challenging Veeva Systems by securing over 40 new clients including a top global pharma leader.
Veeva Dominates Pharma CRM Market with 80% Share
Explore how Veeva holds over 80% market share in pharmaceutical CRM software, cementing its leadership in the industry.
Salesforce Challenges Veeva in Pharma CRM Market
Salesforce Inc. is intensifying its competition with Veeva Systems Inc. to capture a significant share of the pharmaceutical CRM software market.